Neuronetics (STIM) Common Equity (2016 - 2026)

Neuronetics (STIM) has 11 years of Common Equity data on file, last reported at $13.3 million in Q1 2026.

• Quarterly Common Equity fell 66.44% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 66.44% YoY) and the FY2025 annual result came in at $22.4 million, down 29.63% from the prior year.
• Common Equity slipped to $13.3 million in Q1 2026 per STIM's latest filing, from $22.4 million in the prior quarter.
• Across five years, Common Equity topped out at $76.6 million in Q1 2022 and bottomed at $9.4 million in Q3 2024.
• The 5-year median for Common Equity is $34.2 million (2023), against an average of $38.7 million.
• The widest annual swing landed in 2024, when Common Equity sank 75.27%; it then jumped 234.29% in 2025.
• Tracing STIM's Common Equity over 5 years: stood at $57.1 million in 2022, then tumbled by 40.08% to $34.2 million in 2023, then retreated by 6.99% to $31.8 million in 2024, then retreated by 29.63% to $22.4 million in 2025, then plunged by 40.72% to $13.3 million in 2026.
• Per Business Quant, the three latest STIM Common Equity figures stand at $13.3 million (Q1 2026), $22.4 million (Q4 2025), and $31.4 million (Q3 2025).

Peer Comparison